Skip to main content
. Author manuscript; available in PMC: 2021 Mar 15.
Published in final edited form as: Cancer Res. 2020 Jun 19;80(18):3920–3932. doi: 10.1158/0008-5472.CAN-19-3685

Figure 6. IL-6 drives enrichment of donor Th17 over Treg cells at the tumor.

Figure 6.

A) Schematic for ACT of 0.4×106 Th17 cells. B) Tumor infiltration by donor (VB14+CD45.2+) cells or host Tregs one-week post ACT. NT, n=6; treated n=13/group from one experiment. C) FoxP3 expression in donor Th17 product in vitro. 3 independent cultures. D) FoxP3+ cells within donor populations 7 days post ACT. n=13/group from one experiment. E) Tumor FoxP3+ donor cells versus serum IL-6 7 days post ACT. n=39 mice, representative of two experiments. F) ACT of 0.4×106 Day 4 Th17 cells. Anti-IL-6R or isotype control were administered. G) Frequency of FoxP3+ cells within donor populations. n=10mice/group. H) Proposed model. Statistics: B, C, D, G) Mann Whitney U test, E) Spearman correlation. ns: not significant, *p<0.05, **p<0.01, ***p<0.001.